Jorge E Gomez
Mount Sinai Hospital · 115 works · 4,063 citations · h-index 28
Top works
- Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
- Developing a cancer‐specific geriatric assessment
- Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.
- Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein
- Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC)
- A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer
- The Non–Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome
- Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: Results of a randomized pilot trial
- Complementary Therapies and Integrative Oncology in Lung Cancer
- Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer
- An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
- Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
- Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin
- Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma
- Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients
- Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER–Medicare analysis
- Prognostic Significance of Visceral Pleural Involvement in Early-Stage Lung Cancer
- A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
- A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors
- Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)